Publication at Faculty of Medicine in Pilsen |
2017
Abstract
Targeted biological therapy has been shown to result in significant extension of duration and quality of life in patients with advanced non-small-cell lung cancer containing EML-4 ALK gene translocation. This type of tumour is commonly demonstrated in 3-5% of patients with lung adenocarcinoma.
Ceritinib is an effective second-generation ALK tyrosine kinase inhibitor. It is administered orally once daily.
The drug is approved in patients with advanced non-small-cell ALK-positive lung cancer after previous failure of therapy with crizotinib. It is well-tolerated with manageable undesirable effects.
The author describes his first experience with administration of the drug in two patients.